<?xml version="1.0" encoding="UTF-8"?>
<p id="p0275">Chlorpromazine inhibits the clathrin-mediated endocytosis influencing the transport of clathrin and AP2, which is one of the possible ways of viral entry into the host cells. Caveolae and/or lipid rafts precipitate are also used by viruses (e.g. SARS-CoV) for entering into the cells. Moreover, the drug inhibits MERS-CoV (
 <xref rid="bib31" ref-type="bibr">Inoue et al., 2007</xref>; 
 <xref rid="bib9" ref-type="bibr">de Wilde et al., 2014</xref>; 
 <xref rid="bib11" ref-type="bibr">Dyall et al., 2014</xref>), SARS-CoV (
 <xref rid="bib31" ref-type="bibr">Inoue et al., 2007</xref>; 
 <xref rid="bib57" ref-type="bibr">Wang et al., 2008</xref>), HCoV-229E-GFP (
 <xref rid="bib9" ref-type="bibr">de Wilde et al., 2014</xref>; 
 <xref rid="bib46" ref-type="bibr">Pillaiyar et al., 2020</xref>), HCV (
 <xref rid="bib6" ref-type="bibr">Chamoun-Emanuelli et al., 2013</xref>; 
 <xref rid="bib12" ref-type="bibr">Dyall et al., 2017</xref>; 
 <xref rid="bib16" ref-type="bibr">Gastaminza et al., 2010</xref>), MHV (
 <xref rid="bib5" ref-type="bibr">Burkard et al., 2014</xref>), CHIKV (
 <xref rid="bib12" ref-type="bibr">Dyall et al., 2017</xref>) and SFV (
 <xref rid="bib47" ref-type="bibr">Pohjala et al., 2011</xref>) replication 
 <italic>in vitro</italic> in low molecular concentrations. Thus, chlorpromazine can be used as a potential broad-spectrum inhibitor of viruses using the clathrin-mediated endocytosis such as WNV (
 <xref rid="bib8" ref-type="bibr">Chu and Ng, 2004</xref>; 
 <xref rid="bib11" ref-type="bibr">Dyall et al., 2014</xref>), HIV-1 (
 <xref rid="bib3" ref-type="bibr">Beignon et al., 2005</xref>), HCV (
 <xref rid="bib6" ref-type="bibr">Chamoun-Emanuelli et al., 2013</xref>; 
 <xref rid="bib12" ref-type="bibr">Dyall et al., 2017</xref>; 
 <xref rid="bib16" ref-type="bibr">Gastaminza et al., 2010</xref>), EBOV (
 <xref rid="bib4" ref-type="bibr">Bhattacharyya et al., 2010</xref>; 
 <xref rid="bib12" ref-type="bibr">Dyall et al., 2017</xref>), JEV (
 <xref rid="bib12" ref-type="bibr">Dyall et al., 2017</xref>; 
 <xref rid="bib44" ref-type="bibr">Nawa et al., 2003</xref>), HCoV-229E-GFP (
 <xref rid="bib9" ref-type="bibr">de Wilde et al., 2014</xref>; 
 <xref rid="bib46" ref-type="bibr">Pillaiyar et al., 2020</xref>), MERS-CoV (
 <xref rid="bib11" ref-type="bibr">Dyall et al., 2014</xref>; 
 <xref rid="bib31" ref-type="bibr">Inoue et al., 2007</xref>; 
 <xref rid="bib9" ref-type="bibr">de Wilde et al., 2014</xref>), and SARS-CoV (
 <xref rid="bib31" ref-type="bibr">Inoue et al., 2007</xref>; 
 <xref rid="bib57" ref-type="bibr">Wang et al., 2008</xref>). The summarized concentrations of the analyzed drugs inhibiting RNA viruses replication were shown in 
 <xref rid="tbl3" ref-type="table">Table 3</xref> . Moreover, the drug inhibits PEDV (
 <xref rid="bib58" ref-type="bibr">Wei et al., 2020</xref>) invasion. Noteworthy, the antiviral activity of chlorpromazine towards HCV is very promising as the obtained by 
 <xref rid="bib6" ref-type="bibr">Chamoun-Emanuelli et al. (2013)</xref> results (IC
 <sub>50</sub> = 1.47 ± 0.32 μM and CC
 <sub>50</sub>/IC
 <sub>50</sub> = 6) (
 <xref rid="bib6" ref-type="bibr">Chamoun-Emanuelli et al., 2013</xref>) since both values are lower or very near of the toxic human plasma concentration. A similar situation was observed in the case of CCHFV treatment by 
 <xref rid="bib13" ref-type="bibr">Ferraris et al. (2015)</xref>. The stronger effect of the drug towards Huh7 than Vero E6 cells was noticed. The IC
 <sub>50</sub> value for 87–07 strain and Huh7 cells was 4.3 μM, which is in the range of toxic human plasma concentration (
 <xref rid="bib13" ref-type="bibr">Ferraris et al., 2015</xref>). On the other hand, the role of chlorpromazine in JEV treatment is debatable since in the concentration range 2.5–20 μg/ml inhibition of viral binding to Vero cells was not observed, while the drug in the concentration of 10 μg/ml affects the clathrin distribution within a cell with inhibition of JEV uptake (
 <xref rid="bib44" ref-type="bibr">Nawa et al., 2003</xref>).
</p>
